Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 31116076
Shiloh R, Bialik S, Kimchi A (2019) Ser289 phosphorylation activates both DAPK1 and DAPK2 but in response to different intracellular signaling pathways. Cell Cycle 18, 1169-1176 31116076
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.

S289-p - DAPK1 (human)
Modsite: QALSRKAsAVNMEkF SwissProt Entrez-Gene
Orthologous residues
DAPK1 (human): S289‑p, DAPK1 iso3 (human): S289‑p, DAPK1 (mouse): S289‑p, DAPK1 (rat): S289‑p
Methods used to characterize site in vivo immunoprecipitation, mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  colorectal cancer, colorectal carcinoma
Relevant cell lines - cell types - tissues:  HCT116 (intestinal)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE DAPK1 (human)
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester increase
resveratrol decrease
Downstream Regulation
Effect of modification (function):  enzymatic activity, induced
Effect of modification (process):  signaling pathway regulation
Comments:  MAPK-DAPK1 signaling pathway